Ceramides improve atherosclerotic cardiovascular disease risk assessment beyond standard risk factors.
Level 5 - mechanism / opinion, no new human data
Narrative review discussing biological mechanisms and clinical utility without original data or systematic review methodology
PubMed 33058843 · doi:10.1016/j.cca.2020.10.005
What was done
This paper is a narrative review examining the biological mechanisms of ceramides in cardiometabolic disease and evaluating their clinical utility as blood biomarkers for atherosclerotic cardiovascular disease risk stratification using mass spectrometry.
What was found
The abstract reports no numerical data, effect sizes, or statistical metrics. It describes mechanistic links where ceramides accumulate in atherosclerotic plaques and promote LDL endothelial infiltration and aggregation, and notes that clinical studies indicate plasma ceramide levels provide independent prognostic value for cardiovascular outcomes beyond standard risk factors like LDL cholesterol.
Why it matters
Ceramides may serve as an adjunct biomarker to standard lipid profiling, potentially improving cardiovascular risk assessment in patients with cardiometabolic disease.
Limits
The abstract provides no original empirical data, quantitative effect estimates, or systematic review methodology. Specific ceramide species, diagnostic cutoffs, patient cohort details, and comparative cost-effectiveness data are not described.
Cited by
- supports The Mayo Clinic has a clinical ceramide score that predicts cardiovascular disease prognosis.